HØRSHOLM

Three-month interim report (Q1) 2024 (unaudited) 

Retrieved on: 
Thursday, May 2, 2024
ALK, DKK, Growth, Capital market

Launch preparations continue to progress as planned ahead of the expected launches in 2024/25.

Key Points: 
  • Launch preparations continue to progress as planned ahead of the expected launches in 2024/25.
  • ALK is implementing a number of optimisation and prioritisation initiatives in 2024 to free up approximately DKK 250 million in 2025 for strategic growth investments and support of its earnings ambitions.
  • These initiatives are expected to entail one-off costs of approximately DKK 60 million in 2024, that have been included in the earnings outlook which is unchanged.
  • Commenting on the Q1 results, CEO Peter Halling said: “2024 started well for ALK.

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Retrieved on: 
Wednesday, April 17, 2024
Patient, Safety, Pembrolizumab, Trial of the century, CSO, Biology, Hollywood Private Hospital, Pharmaceutical industry

The Company initiated its Phase 2 clinical study in September 2022 to assess the efficacy, safety and ability to induce a tumor-specific immune response of the EVX-01 cancer vaccine in metastatic melanoma patients.

Key Points: 
  • The Company initiated its Phase 2 clinical study in September 2022 to assess the efficacy, safety and ability to induce a tumor-specific immune response of the EVX-01 cancer vaccine in metastatic melanoma patients.
  • The EVX-01 vaccine was designed using Evaxion’s proprietary AI-Immunology™ platform and is an individualized therapy matching the unique tumor profile and characteristics of the patient’s immune system.
  • Each patient enrolled in the trial receives a unique vaccine designed and manufactured based on their individual biology.
  • Patients are administered ten EVX-01 doses over a period of 78 weeks in combination with the anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Retrieved on: 
Tuesday, April 2, 2024
S. aureus, Risk, Patient, Tissue, Staphylococcus aureus, Infection, CDC, Staphylococcus, Animal, Antigen, Vaccine

In the animal studies, the EVX-B1 antigens significantly reduced disease burden.

Key Points: 
  • In the animal studies, the EVX-B1 antigens significantly reduced disease burden.
  • Birgitte Rønø, Chief Scientific Officer at Evaxion, expresses enthusiasm: “We are very thrilled about the encouraging data and believe that our EVX-B1 vaccine antigens hold the potential for efficacy in human trials – a milestone that previous vaccine attempts have failed to achieve.”
    There is no S. aureus vaccine available for human use.
  • Also, the presence of antibiotic-resistant S. aureus is limiting available treatment options.
  • The Centers for Disease Control and Prevention (CDC) has reported 120,000 bloodstream infections associated with S. aureus in the US annually.

Evaxion Announces Business Update and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
MSD, Conference, Innovation, Patient, Merck, Koala retrovirus, AI, Cancer, GHI, Merck & Co., Machine learning, European, Artificial intelligence

Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA.

Key Points: 
  • Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA.
  • MSD GHI is now the single largest shareholder in Evaxion, with ownership of around 15%.
  • COPENHAGEN, Denmark, March 27, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
  • Evaxion hosted an R&D Day on March 19, 2024, providing deeper insights into the validated and differentiated AI-Immunology™ platform.

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Retrieved on: 
Tuesday, March 19, 2024
MSD, EST, Koala retrovirus, Learning, AI, Neoplasm, Immune system, Machine learning, Vaccine, Collection, Medical device

The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here .

Key Points: 
  • The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here .
  • The R&D Day features a series of talks providing in-depth insights into Evaxion's clinically validated AI-Immunology™ platform for vaccine target discovery, design and development.
  • Christian Kanstrup, CEO of Evaxion, expresses enthusiasm: “We have been looking forward to this exciting day and welcome everyone interested in learning more about our technology and its potential for saving and improving lives.
  • We believe that we hold a truly differentiated position driven by our validated AI-Immunology™ platform and the multi-disciplinary capability set we have built around it.

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Retrieved on: 
Thursday, February 29, 2024
EST, Infection, Patient, Research and development, Cancer

The R&D Day will feature a series of talks from Evaxion’s scientists and bioinformaticians, providing insights into Evaxion’s validated AI-Immunology™ platform for vaccine target discovery, design and development.

Key Points: 
  • The R&D Day will feature a series of talks from Evaxion’s scientists and bioinformaticians, providing insights into Evaxion’s validated AI-Immunology™ platform for vaccine target discovery, design and development.
  • The event will highlight the unique predictive capabilities that differentiate the platform and how these can help address severe unmet medical needs for patients with cancer and infectious diseases.
  • The event will take place at Evaxion’s facilities in Hørsholm, Denmark, and will also be accessible via live webcast.
  • A replay of the presentations will be available on our website following the event.

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Retrieved on: 
Tuesday, February 20, 2024
MSD, Infection, Organization, Merck, Merck & Co., AI, Vaccine, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).

Key Points: 
  • COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA).
  • Further, we are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase.
  • Using Evaxion's proprietary platform, AI-Immunology™, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues.
  • The conclusion of the antigen discovery and design phases marks a significant milestone for the development of the vaccine candidate, EVX-B3.

Annual General Meeting in ALK-Abelló A/S on 14 March 2024

Retrieved on: 
Friday, February 16, 2024
A/S, Annual, OMX, AGM

ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark.

Key Points: 
  • ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark.
  • The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.
  • For further information please contact:

Annual report 2023: ALK delivers 9% sales growth with profits up 50%

Retrieved on: 
Thursday, February 8, 2024
DKK, SCIT, ALK, Growth, Management, Annual report, Tablet, Online shopping

Revenue increased by 9% to DKK 4,824 million (4,511) based on growth in all sales regions.

Key Points: 
  • Revenue increased by 9% to DKK 4,824 million (4,511) based on growth in all sales regions.
  • Tablet sales increased by 11% to DKK 2,296 million (2,102).
  • European tablet sales regained momentum in the second half-year with 13% growth.
  • ALK expects broad-based growth across sales regions and product groups in 2024 with tablet sales being key to growth.

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Wednesday, February 7, 2024
Letter, Notification

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that on February 05, 2024, it received a Notification Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2).
  • The Notification Letter confirmed that the closing bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater for ten consecutive business days from January 22, 2024, to February 02, 2024, and that the Company has regained compliance with the listing rules of the Nasdaq Capital Market.